cognitive cybersecurity intelligence

News and Analysis

Search

Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

UCB has presented the first pooled data analysis from phase 3 trials of its bimekizumab treatment for moderate to severe hidradenitis suppurativa at the European Academy of Dermatology and Venereology (EADV) Congress. The analysis showed the treatment led to clinically important improvements and a large percentage of patients who achieved a high skin response after 16 weeks maintained their response up to 48 weeks.

Source: www.prnewswire.com –

Subscribe to newsletter

Subscribe to HEAL Security Dispatch for the latest healthcare cybersecurity news and analysis.

More Posts

Connecting Tech to Black America

Tech evangelist David Lee spotlights the underrepresentation of Black Americans in tech, an issue he contends requires collective action to rectify. He suggests fostering connections

Zero-Day Attack Hits Cybersecurity Leader

The MITRE Corporation, a contributor to public interest cybersecurity, disclosed a data breach originating from a state-backed hack. Detected after suspicous activity was noticed on

Defining and Understanding Trust Assurance

Trust is essential for businesses and building it requires embracing the pillars of trust assurance: predictive, integrated, and transparent systems. Through trust assurance, businesses can